此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

阿立哌唑长期维持治疗与自闭症相关的易激惹儿科患者的安全性和有效性

The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.

研究概览

研究类型

介入性

注册 (实际的)

215

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Dothan、Alabama、美国、36303
        • Harmonex Neuroscience Research, Inc
    • Arizona
      • Phoenix、Arizona、美国、85006
        • Southwest Autism Research And Resource Center
    • California
      • Costa Mesa、California、美国、92626
        • Clinical Innovations, Inc.
      • Glendale、California、美国、91206
        • Behavioral Research Specialists, Llc
      • Palo Alto、California、美国、94306
        • Abbey Neuropsychology Clinic
      • San Francisco、California、美国、94143
        • Ucsf - Lppi
      • Stanford、California、美国、94305
        • Stanford University School Of Medicine
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20010
        • Children'S National Medical Center
    • Florida
      • Gainesville、Florida、美国、32607
        • Sarkis Clinical Trials
      • Hialeah、Florida、美国、33012
        • Palm Springs Research Institute
      • Maitland、Florida、美国、32751
        • Florida Clinical Research Center, Llc
      • Miami、Florida、美国、33155
        • Miami Children'S Hospital
      • Tampa、Florida、美国、33613
        • University Of South Florida
    • Georgia
      • Smyrna、Georgia、美国、30080
        • Institute For Behavioral Medicine, Llc
    • Idaho
      • Coeur d'Alene、Idaho、美国、83814
        • Kootenai Behavioral Health Center
    • Kentucky
      • Louisville、Kentucky、美国、40202
        • Kosair Charities Pediatric Clinical Research Unit
    • Louisiana
      • Shreveport、Louisiana、美国、71103
        • Lsu Health Sciences Center
    • Massachusetts
      • Newton、Massachusetts、美国、02459
        • Neurocare, Inc.
    • Michigan
      • Bloomfield Hills、Michigan、美国、48302
        • Neurobehavioral Medicine Group
    • Nevada
      • Las Vegas、Nevada、美国、89128
        • Center For Psychiatry And Behavioral Medicine, Inc
    • New Jersey
      • Gibbsboro、New Jersey、美国、08026
        • Clinical Research Center Of New Jersey
      • Toms River、New Jersey、美国、08755
        • Children'S Specialized Hosp
    • New York
      • Stony Brook、New York、美国、11794
        • Stony Brook University School Of Medicine
    • North Carolina
      • Chapel Hill、North Carolina、美国、27517
        • Unc Chapel Hill
    • Ohio
      • Cleveland、Ohio、美国、44106
        • University Hospitals Case Medical Center
      • Cleveland、Ohio、美国、44104
        • Cleveland Clinic
      • Columbus、Ohio、美国、43210
        • The Ohio State University Nisonger Center
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73116
        • Cutting Edge Research Group
      • Oklahoma City、Oklahoma、美国、73117
        • Ou Physician'S Child Study Center
      • Tulsa、Oklahoma、美国、74104
        • Tulsa Clinical Research, Llc
    • Oregon
      • Gresham、Oregon、美国、97030
        • Cyn3rgy Research
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19124
        • Drexel University College Of Medicine
      • Pittsburgh、Pennsylvania、美国、15203
        • Western Psychiatric Institute And Clinic
    • Tennessee
      • Kingsport、Tennessee、美国、37660
        • Holston Medical Group
    • Texas
      • DeSoto、Texas、美国、75115
        • Insite Clinical Research
    • Utah
      • Clinton、Utah、美国、84015
        • Ericksen Research And Development
    • Virginia
      • Norfolk、Virginia、美国、23510
        • Childrens Specialty Gr., Pllc
      • Richmond、Virginia、美国、23298
        • Virginia Treatment Center For Children

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 至 17年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
  • Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
  • Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
  • Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
  • An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
  • Mental age of at least 24 months

Key Exclusion Criteria:

  • Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
  • Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
  • Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
  • Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
  • History of neuroleptic malignant syndrome
  • At significant risk for suicide based on history or routine psychiatric status examination
  • A seizure within the past year
  • History of severe head trauma or stroke
  • History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
  • Weight lower than 15 kg
  • Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
  • History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
  • Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂

Tablets, oral, 0 mg, once daily, 16 weeks

实验性的:阿立哌唑

Tablets, oral, 2-15 mg, once daily, 13-42 weeks

其他名称:
  • 能力化
  • BMS-337039

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Patients Relapsing by Week 16
大体时间:From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment.

From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

次要结果测量

结果测量
措施说明
大体时间
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
大体时间:From Baseline (end of Phase 1) to Week 16 of Phase 2

ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
大体时间:From Baseline (end of Phase 1) to Week 16 of Phase 2

CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
大体时间:Up to 26 weeks

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Up to 26 weeks

其他结果措施

结果测量
措施说明
大体时间
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
大体时间:Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2011年3月7日

初级完成 (实际的)

2012年6月20日

研究完成 (实际的)

2012年6月20日

研究注册日期

首次提交

2010年10月22日

首先提交符合 QC 标准的

2010年10月22日

首次发布 (估计的)

2010年10月25日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月9日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅